← Back to Search
Other
NX-5948 Study in Healthy Subjects
Lincoln, NE
Phase 1
Waitlist Available
Research Sponsored by Nurix Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Healthy, adult, male, 18-55 years of age
Be between 18 and 65 years old
Must not have
Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study
Previous exposure to NX-5948
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 9 weeks
Awards & highlights
No Placebo-Only Group
Summary
This trial aims to study how the body processes a new drug called NX-5948. In the first phase, researchers will look at how the drug affects the body and explore potential biomarkers. The
See full description
Who is the study for?
This clinical trial is open to healthy individuals. Specific eligibility criteria are not provided, but typically participants must meet certain health standards and may be required to have specific characteristics relevant to the study's objectives.Check my eligibility
What is being tested?
The study is testing NX-5948, a new drug. It involves two periods: the first looks at how the drug affects the body (pharmacodynamics) and biomarkers; the second measures total radioactivity in the body and breaks down its components (metabolite profiling).See study design
What are the potential side effects?
Since this is an early-stage trial for NX-5948 in healthy subjects, detailed side effects are not listed. However, common side effects in such trials can include nausea, headache, dizziness or reactions at the administration site.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am a healthy man aged between 18 and 55.
show original
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I am mentally capable and do not have significant emotional issues.
show original
Select...
I have been treated with NX-5948 before.
show original
Select...
I have not been exposed to high levels of radiation or radioisotopes in the last year and will not be in the next year.
show original
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 9 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~9 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Assessment of bioavailability with oral dosing of NX-5948
Assessment of total radioactivity after oral dosing with NX-5948
Assessment of whole blood to plasma ratio for TRA after oral dosing with NX-5948
+4 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Active Treatment Arm IV and OralExperimental Treatment1 Intervention
This single Arm will include a single dose by IV and a single dose given by mouth for all 8 subjects.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
NX-5948
2024
Completed Phase 1
~10
Find a Location
Closest Location:Celerion· Lincoln, NE
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Nurix Therapeutics, Inc.Lead Sponsor
6 Previous Clinical Trials
1,140 Total Patients Enrolled
Sarah Injac, MD PhDStudy DirectorNurix Therapeutics, Inc.
1 Previous Clinical Trials
32 Total Patients Enrolled